For the first time, children in the United States will have a non-drug option for treating attention deficit hyperactivity disorder (ADHD). The FDA just cleared the Monarch external Trigeminal Nerve Stimulation (eTNS) System from NeuroSigma, a Los Angeles, California company, to treat ADHD in kids between 7 and 12 years old. The system has already (Read more...)
New Device Cleans Blood to Treat Preeclampsia
Preeclampsia is one of the most common serious maladies that pregnant women encounter. It is a poorly understood condition with symptoms such as high blood pressure, proteinuria, and headaches, potentially even leading to seizures. The treatment options for preeclampsia are still very limited, mostly confined to hypertension medications, bed rest, (Read more...)
Uncategorized
Parkhurst NuVision Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts
SAN ANTONIO–(BUSINESS WIRE)–Parkhurst NuVision in San Antonio, Texas, is participating in the AcuFocus clinical study for the IC-8 intraocular lens designed for cataracts.
Uncategorized
Research shows microglia may control neuroinflammation
Research from Massachusetts Eye and Ear has shown that microglia may serve as facilitators of neuroinflammation in autoimmune uveitis.Researchers described in a press release the role of microglia in directing the initiation of autoimmune uveitis by or…
MIXiii-BIOMED 2019 Conference – Early Registration by Wednesday, May 1
This is the last week to register at the discounted early registration rates for the 18th MIXiii-BIOMED Conference and Exhibition, taking place May 14-16 at The David InterContinental Hotel, Tel Aviv, Israel. As Israel’s leading life science industry event, MIXiii-BIOMED is the main annual meeting place for members of Isra (Read more...)
Uncategorized
FDA approves generic tobramycin from Alembic
The FDA has approved an abbreviated new drug application for Alembic Pharmaceuticals’ tobramycin ophthalmic solution USP 0.3%, according to a press release.The generic drug, which is equivalent to Tobrex ophthalmic solution 0.3% (Novartis), is indicate…